Lexeo Therapeutics ownership disclosure: Suvretta Capital Management, LLC reports shared beneficial ownership of 5,674,778 shares (7.7%) of common stock, and Averill Master Fund, Ltd. reports shared beneficial ownership of 4,827,730 shares (6.5%). Aaron Cowen is reported with shared beneficial ownership of 5,674,778 shares (7.7%). The schedule states these securities are directly owned by advisory clients of Suvretta and includes a joint filing agreement and control-person identification.
Positive
None.
Negative
None.
Insights
Large passive holdings disclosed by an investment adviser and an affiliated fund.
Su v retta Capital and Averill Master Fund are reported as holding 5,674,778 and 4,827,730 shares respectively, representing 7.7% and 6.5% of the class. The holdings are shown as shared voting and shared dispositive power.
The filing notes the shares are held for advisory clients and includes a joint filing agreement and an exhibit identifying the control person. Subsequent SEC schedules could show changes if these advisory clients alter positions.
Reporting emphasizes shared authority and advisory-client ownership.
The schedule discloses zero sole voting or dispositive power and records shared powers for voting and disposition, which signals control via advisory arrangements rather than direct individual ownership. A signed disclaimer accompanies the filing.
Watch for any amendments that change classification (e.g., Schedule 13D) or disclose additional parties named in Exhibit B; timing for such updates is not stated here.
Key Figures
Suvretta shares reported:5,674,778 sharesAverill shares reported:4,827,730 sharesPercent of class (Suvretta/Cowen):7.7%+1 more
4 metrics
Suvretta shares reported5,674,778 sharesshared beneficial ownership reported on Schedule 13G
Averill shares reported4,827,730 sharesshared beneficial ownership reported on Schedule 13G
Percent of class (Suvretta/Cowen)7.7%percent of common stock reported for Suvretta Capital and Aaron Cowen
Percent of class (Averill)6.5%percent of common stock reported for Averill Master Fund, Ltd.
Key Terms
shared dispositive power, beneficial ownership, Joint Filing Agreement, control person identification
4 terms
shared dispositive powerregulatory
"Shared Dispositive Power 5,674,778.00"
beneficial ownershipregulatory
"Amount beneficially owned: Suvretta Capital Management, LLC - 5,674,778"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Joint Filing Agreementlegal
"Exhibit A - Joint Filing Agreement"
control person identificationlegal
"Exhibit B - Control Person Identification"
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Lexeo Therapeutics, Inc.
(Name of Issuer)
Common stock, par value $0.0001
(Title of Class of Securities)
52886X107
(CUSIP Number)
04/06/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
52886X107
1
Names of Reporting Persons
SUVRETTA CAPITAL MANAGEMENT, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
5,674,778.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
5,674,778.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
5,674,778.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.7 %
12
Type of Reporting Person (See Instructions)
IA, OO
SCHEDULE 13G
CUSIP Number(s):
52886X107
1
Names of Reporting Persons
Averill Master Fund, Ltd.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,827,730.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,827,730.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,827,730.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.5 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
CUSIP Number(s):
52886X107
1
Names of Reporting Persons
AARON COWEN
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
5,674,778.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
5,674,778.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
5,674,778.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.7 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Lexeo Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
345 Park Avenue South, Floor 6, New York, NY, 10010
Item 2.
(a)
Name of person filing:
Suvretta Capital Management, LLC
Averill Master Fund, Ltd.
Aaron Cowen
(b)
Address or principal business office or, if none, residence:
Suvretta Capital Management, LLC
540 Madison Avenue, 7th Floor
New York, New York 10022
United States of America
Averill Master Fund, Ltd.
c/o Maples Corporate Services Limited
P.O. Box 309
Ugland House
Grand Cayman KY1-1104
Cayman Islands
Aaron Cowen
c/o Suvretta Capital Management, LLC
540 Madison Avenue, 7th Floor
New York, New York 10022
(c)
Citizenship:
Suvretta Capital Management, LLC - Delaware
Averill Master Fund, Ltd. - Cayman Islands
Aaron Cowen - United States
(d)
Title of class of securities:
Common stock, par value $0.0001
(e)
CUSIP Number(s):
52886X107
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
All of the securities reported in this Schedule 13G are directly owned by advisory clients of Suvretta Capital Management, LLC. None of those advisory clients, other than Averill Master Fund, Ltd., may be deemed to beneficially own more than 5% of the Common stock, $0.0001 par value.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
Please see Exhibit B attached hereto.
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
SUVRETTA CAPITAL MANAGEMENT, LLC
Signature:
By: /s/ Andrew Nathanson
Name/Title:
Andrew Nathanson, General Counsel and Chief Compliance Officer
Date:
04/13/2026
Averill Master Fund, Ltd.
Signature:
By: /s/ Andrew Nathanson
Name/Title:
Andrew Nathanson, Authorized Signatory
Date:
04/13/2026
AARON COWEN
Signature:
By: /s/ Aaron Cowen
Name/Title:
Aaron Cowen
Date:
04/13/2026
Comments accompanying signature: * Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his, her or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
To the extent that "ownership of 5 percent or less of a class" was indicated in Item 5, such response only applies to the Reporting Person(s) that indicated elsewhere herein that it beneficially owns five percent (5%) or less of the class.
Exhibit Information
Exhibit A - Joint Filing Agreement
Exhibit B - Control Person Identification
What stake does Suvretta Capital hold in Lexeo Therapeutics (LXEO)?
Suvretta Capital is reported with shared beneficial ownership of 5,674,778 shares, representing 7.7% of Lexeo Therapeutics' common stock. The filing states these shares are owned by advisory clients of Suvretta.
How much does Averill Master Fund, Ltd. own of LXEO?
Averill Master Fund, Ltd. is reported with shared beneficial ownership of 4,827,730 shares, equal to 6.5% of the class. The filing lists the fund as a Cayman Islands-registered entity.
Does Aaron Cowen personally own the reported LXEO shares?
Aaron Cowen is shown with shared beneficial ownership of 5,674,778 shares (7.7%). The filing includes a disclaimer stating reporting persons disclaim beneficial ownership except to the extent of pecuniary interest.
Are the reported holdings sole or shared voting power for LXEO shares?
The schedule reports 0 shares of sole voting power and shared voting and dispositive power for the reported amounts: 5,674,778 (Suvretta/Cowen) and 4,827,730 (Averill).
What exhibits accompany this Schedule 13G filing for LXEO?
The filing includes Exhibit A (Joint Filing Agreement) and Exhibit B (Control Person Identification). Signatures are provided by authorized signatories and Aaron Cowen.
